阿巴洛肽在绝经后骨质疏松症女性中的心血管安全性:ACTIVE 3期试验分析
基于ACTIVE 3期试验(2463例绝经后骨质疏松症女性随机接受阿巴洛肽、特立帕肽或安慰剂治疗18个月)及其延伸研究ACTIVExtend和一项55名健康成人药理学研究,评估阿巴洛肽的心血管安全性。阿巴洛肽和特立帕肽相对于安慰剂短暂增加心率,首次给药后1小时心率平均变化分别为7.9和5.3次/分(安慰剂1.2次/分),健康志愿者心率增加在4小时内消退。严重心脏不良事件各组相似(0.9%-1.0%),事后分析中阿巴洛肽和特立帕肽至首次MACE+HF时间较安慰剂延长(P=0.02和P=0.04)。
要点
- 阿巴洛肽和特立帕肽相对于安慰剂短暂增加心率,首次给药后1小时平均变化分别为7.9和5.3次/分。
- 健康志愿者中心率增加在4小时内消退,仰卧位收缩压和舒张压1小时平均变化分别为-2.7/-3.6 mmHg(阿巴洛肽)、-2.0/-3.6(特立帕肽)、-1.5/-2.3(安慰剂)。
- 严重心脏不良事件各组相似(0.9%-1.0%),事后分析中阿巴洛肽和特立帕肽至首次MACE+HF时间较安慰剂延长(P=0.02和P=0.04)。
核心结论
- 阿巴洛肽与绝经后骨质疏松症女性短暂心率增加和血压小幅降低相关,未增加严重心脏不良事件、MACE或HF风险。
研究设计与样本
- ACTIVE(NCT01343004)为3期试验,将2463例绝经后骨质疏松症女性随机分配至阿巴洛肽、特立帕肽或安慰剂组治疗18个月。
- ACTIVExtend(NCT01657162)中,阿巴洛肽组和安慰剂组参与者接受阿仑膦酸钠治疗2年。
- 还包括一项在55名健康成人中进行的药理学研究。
主要发现
- 首次给药后,从治疗前至治疗后1小时的平均(标准差)心率变化:阿巴洛肽组7.9(8.5)次/分,特立帕肽组5.3(7.5)次/分,安慰剂组1.2(7.1)次/分。
- 健康志愿者中心率增加在4小时内消退。
- 治疗后1小时平均仰卧位收缩压和舒张压变化:阿巴洛肽组-2.7/-3.6 mmHg,特立帕肽组-2.0/-3.6 mmHg,安慰剂组-1.5/-2.3 mmHg。
- 严重心脏不良事件参与者百分比各组相似(0.9%-1.0%)。
- 事后分析中,至首次MACE+HF发生时间阿巴洛肽组较安慰剂组延长(P=0.02),特立帕肽组较安慰剂组延长(P=0.04)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. OBJECTIVES: We assessed the cardiovascular safety profile of abaloparatide. DESIGN: Review of heart rate (HR), blood pressure (BP), and cardiovascular-related adverse events (AEs), including major adverse cardiovascular events (MACEs) and heart failure (HF) from: (a) ACTIVE (NCT01343004), a phase 3 trial that randomized 2463 postmenopausal women with osteoporosis to abaloparatide, teriparatide, or placebo for 18 months; (b) ACTIVExtend (NCT01657162), where participants from the abaloparatide and placebo arms received alendronate for 2 years; and (c) a pharmacology study in 55 healthy adults. RESULTS: Abaloparatide and teriparatide transiently increased HR relative to placebo. Following first dose, mean (standard deviation [SD]) HR change from pretreatment to 1 hour posttreatment was 7.9 (8.5) beats per minute (bpm) for abaloparatide, 5.3 (7.5) for teriparatide, and 1.2 (7.1) for placebo. A similar pattern was observed over subsequent visits. In healthy volunteers, HR increase resolved within 4 hours. The corresponding change in mean supine systolic and diastolic BP 1 hour posttreatment was -2.7/-3.6 mmHg (abaloparatide), -2.0/-3.6 (teriparatide), and -1.5/-2.3 (placebo). The percentage of participants with serious cardiac AEs was similar among groups (0.9%-1.0%). In a post hoc analysis, time to first incidence of MACE + HF was longer with abaloparatide (P = 0.02 vs placebo) and teriparatide (P = 0.04 vs placebo). CONCLUSIONS: Abaloparatide was associated with transient increases in HR and small decreases in BP in postmenopausal women with osteoporosis, with no increase in risk of serious cardiac AEs, MACE, or HF.
引用
- Cosman F, Peterson LR, Towler DA, et al. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial. J Clin Endocrinol Metab. 2020. PMID: 32658264. doi:10.1210/clinem/dgaa450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。